Citations

Clear

4610 citation(s) found for "Lu, Brian".

NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023
Moses, Kelvin A. , Sprenkle, Preston C. , Box, Geoffrey N., Carlsson, Sigrid , Catàlona, William J. , Dahl, Douglas M. , Dall’Era, Marc , Davis, John W. , Epstein, Jonathan I. , Etzioni, Ruth B., Farrington, Thomas A., Garraway, Isla P. , Jarrard, David F. , Kauffman, Eric, Kaye, Deborah R. , Kibel, Adam S. , LaGrange, Chad A. , Maroni, Paul, Ponsky, Lee , Salami, Simpa S. , Shaneyfelt, Terrence, Smaldone, Marc C. , Sonn, Geoffrey A. , Tyson, Mark D. , Vapiwala, Neha , Wake, Robert, Washington, Samuel L. , Yu, Alice , Yuh, Bertram, Berardi, Ryan A., Freedman-Cass, Deborah A., Salami, Simpa S , Bahler, Clinton D. , Drake, Bettina F. , Etzioni, Ruth B., Reys, Brian D. , Sánchez, Alejandro , Seibert, Tyler M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 10, 2023 | Volume: 21 | Issue: 3 | Pages: 236-246

10.6004/jnccn.2023.0014 | PMID 36898362 Get It

The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations for individuals with a prostate who opt to participate in an early detection program after receiving the appropriate counseling on the pros and cons. These NCCN Guidelines Insights provide a summary of recent updates to the NCCN Guidelines with regard to the testing protocol, use of multiparametric MRI, and management of negative biopsy results to optimize the detection of clinically significant prostate cancer and minimize the detection of indolent disease.
Smoking Cessation, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Shields, Peter G. , Balis, David S. , Davis, James M. , Edmondson, Donna, Feliciano, Joy, Hudmon, Karen Suchanek , Jaklitsch, Michael T. , McCarthy, Danielle E. , Ong, Michael , Prochaska, Judith J. , Sandoval, Argelia, Sheffer, Christine E. , Spencer, Sharon, Tindle, Hilary A. , Tong, Elisa K. , Triplette, Matthew , Urbanic, James J., Videtic, Gregory M.M. , Whitlock, C. Will, McCullough, Beth, Darlow, Susan, Warner, David, Thomas, Timothy K , Sheffer, Christine E , Davis, James M , Bierut, Laura Jean , Arenberg, Douglas A. , Cinciripini, Paul M , Hitsman, Brian L. , Leone, Frank T. , Ling, Pamela May , Park, Elyse R , Studts, Jamie L. , Tanvetyanon, Tawee , Warner, David O.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 10, 2023 | Volume: 21 | Issue: 3 | Pages: 297-322

10.6004/jnccn.2023.0013 | PMID 36898367 Get It

Although the harmful effects of smoking after a cancer diagnosis have been clearly demonstrated, many patients continue to smoke cigarettes during treatment and beyond. The NCCN Guidelines for Smoking Cessation emphasize the importance of smoking cessation in all patients with cancer and seek to establish evidence-based recommendations tailored to the unique needs and concerns of patients with cancer. The recommendations contained herein describe interventions for cessation of all combustible tobacco products (eg, cigarettes, cigars, hookah), including smokeless tobacco products. However, recommendations are based on studies of cigarette smoking. The NCCN Smoking Cessation Panel recommends that treatment plans for all patients with cancer who smoke include the following 3 tenets that should be done concurrently: (1) evidence-based motivational strategies and behavior therapy (counseling), which can be brief; (2) evidence-based pharmacotherapy; and (3) close follow-up with retreatment as needed.
Author response: Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study
Luckett, Patrick H. , Fagan, Anne M. , Perrin, Richard J. , Farlow, Martin R. , Mori, Hiroshi , Nübling, Georg, Network, The Dominantly Inherited Alzheimer, Millar, Peter R , Gordon, Brian A. , Benzinger, Tammie L.S. , Cruchaga, Carlos , Hassenstab, Jason , Schindler, Suzanne E. , Allegri, Ricardo , Day, Gregory S. , Nübling, Georg , Network, The Dominantly Inherited Alzheimer, Bateman, Randall J. , Morris, John C. , Ances, Beau M.

Mayo Clinic

No container title available | March 6, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.81869.sa2 Get It

Facial aesthetic minimally invasive procedure: More than just vanity, a social‐psychological approach
Elzen, Helga E. van den, Barends, Ard J. , Vugt, Mark van , Biesman, Brian S. , Alfertshofer, Michael , Cotofana, Sebastian , Cotofana, Sebastian , Alfertshofer, Michael , ELZEN, HELGA J. VAN DEN, Velthuis, Peter J.

Mayo Clinic

Journal of Cosmetic Dermatology | March 5, 2023 | Volume: 22 | Issue: 7 | Pages: 2063-2070

10.1111/jocd.15678 | PMID 36852750 Get It

AbstractBackgroundDue to the great importance of the face in social interaction, minimally invasive treatments can—besides their ability to rejuvenate and enhance beauty—also change the way facial impressions of a person are perceived. In recent literature, three main character traits (attractiveness, trustworthiness, and competence) and subdomains essential for facial perception were described.ObjectiveTo investigate whether minimally invasive procedures truly influence different character traits when evaluated by independent, objective observers.MethodsPhotographs of n = 34 female faces before and after treatment with injectable fillers and botulinum toxin were rated by 393 individuals without aesthetic background with regards to different character traits on a 7‐point Likert scale. Tests for dimensionality were performed, and composite scores of the impressions underlying each of the three dimensions were created and compared using within‐subjects t tests.ResultsTreatments statistically significantly improved the overarching character trait domains attractiveness, trustworthiness, and competence in posttreatment photographs compared with pretreatment. Posttreatment ratings of the respective subdomains also showed a statistically significant difference compared with pretreatment photographs, with the exception of the subdomain dominance which failed to reach statistical significance.ConclusionImpressions of facial attractiveness, trustworthiness, and competence can be improved by injectables while the naturalness of the face is left intact. An implication is that the improvement of traits highly relevant to social interaction will accommodate the patient's desires for beautification and rejuvenation.
Systematic Transmission Electron Microscopy‐Based Identification and 3D Reconstruction of Cellular Degradation Machinery
Neikirk, Kit , Vue, Zer , Katti, Prasanna , Rodriguez, Ben I., Omer, Salem, Shao, Jianqiang, Christensen, Trace , Garza-López, Edgar , Marshall, Andrea G. , Palavicino‐Maggio, Caroline B. , Ponce, Jessica, Alghanem, Ahmad F. , Vang, Larry , Barongan, Taylor , Rodman, Taylor, Stephens, Dominique, Mungai, Margaret , Murray, Sandra , Crabtree, Amber , Pereira, Renata O. , Hinton, Antentor , Glancy, Brian , Abel, E Dale , Hinton, Antentor , Pereira, Renata O , Katti, Prasanna , Murray, Sandra A , Marshall, Andrea G , Beasley, Heather K. , Stephens, Dominique C., Correia, Marcelo , Exil, Vernat , Damo, Steven M. , Glancy, Brian , Abel, E. Dale

Mayo Clinic

Advanced Biology | March 3, 2023 | Volume: 7 | Issue: 6 | Pages: No page available

10.1002/adbi.202200221 | PMID 36869426 Get It

Abstract Various intracellular degradation organelles, including autophagosomes, lysosomes, and endosomes, work in tandem to perform autophagy, which is crucial for cellular homeostasis. Altered autophagy contributes to the pathophysiology of various diseases, including cancers and metabolic diseases. This paper aims to describe an approach to reproducibly identify and distinguish subcellular structures involved in macroautophagy. Methods are provided that help avoid common pitfalls. How to distinguish between lysosomes, lipid droplets, autolysosomes, autophagosomes, and inclusion bodies are also discussed. These methods use transmission electron microscopy (TEM), which is able to generate nanometer‐scale micrographs of cellular degradation components in a fixed sample. Serial block face‐scanning electron microscopy is also used to visualize the 3D morphology of degradation machinery using the Amira software. In addition to TEM and 3D reconstruction, other imaging techniques are discussed, such as immunofluorescence and immunogold labeling, which can be used to classify cellular organelles, reliably and accurately. Results show how these methods may be used to accurately quantify cellular degradation machinery under various conditions, such as treatment with the endoplasmic reticulum stressor thapsigargin or ablation of the dynamin‐related protein 1.
Abstract PD14-05: PD14-05 Prospective longitudinal validation of a breast cancer risk prediction model in a cohort of 130,058 women
Mabey, Brent, Hughes, Elisha , Probst, Braden , Simmons, Timothy , Hullinger, Brooke, Gary, Monique, Klemp, Jennifer R. , Offit, Kenneth , Pruthi, Sandhya , Whitworth, Pat, Wagner, Susanne , Slavin, Thomas P. , Gutin, Alexander , Pederson, Holly J. , Morris, Brian, Domchek, Susan M. , Eng, Charis , Mukherjee, Semanti , Vijai, Joseph , Olopade, Olufunmilayo I. , Kurian, Allison W. , Robson, Mark E. , Lanchbury, Jerry S.

Mayo Clinic

Cancer Research | March 2, 2023 | Volume: 83 | Issue: 5_Supplement | Pages: PD14-05-PD14-05

10.1158/1538-7445.sabcs22-pd14-05 Get It

Abstract Background: Personalized breast cancer (BC) risk assessment depends on known traditional risk factors, specific germline mutations, and genome-wide polygenic risk scores (PRS). PRS explains a substantial proportion of genetic BC susceptibility. Accuracy of BC risk prediction may be improved by combining a PRS with traditional risk factors. We recently developed and validated a 149-SNP PRS for women of diverse ancestries using ancestry-informative genetic markers and combined this with version 7 of the Tyrer-Cuzick (TC) model to generate a Combined Risk Score (CRS). Here, we describe a pre-specified prospective longitudinal clinical validation of CRS as a predictor of BC risk. Methods: Women in the U.S. who were referred for clinical genetic testing between January 2017 and February 2019 were matched to medical and hospital claims in an anonymized dataset. Women with a pathogenic mutation in a BC-related gene were excluded from analysis. Follow-up began 4 months after testing and extended to the earliest date of BC diagnosis, censoring at the time of BC preventive treatment, or November 1, 2019. Incident BC events were determined by an ICD10 code of C50.* and confirmed by relevant treatment codes. CRS calibration was evaluated by the ratio of observed (O) to expected (E) incident BCs for the full cohort, and for women split into event-based 5-year CRS risk deciles. Cox proportional hazards models were used to evaluate discriminatory accuracy in terms of hazard ratios (HR) with 95% confidence intervals (CI) and p-values from likelihood ratio chi-squared statistics. Kaplan-Meier analysis was used to examine risk for women split into high- or low-risk groups according to a 3% 5-year CRS risk threshold. Results: 130,058 women with 148,349 total patient years met study eligibility criteria and were matched to claims data. Over a median (range) follow-up of 12.1 (4.0-29.5) months, 340 incident BC events were observed. The CRS was well calibrated in the overall cohort with an O/E ratio of 1.11 (95% CI=0.99-1.23) and within deciles of predicted risk (Table). Importantly, in the highest risk decile, the O/E was 0.91 (95% CI=0.63-1.27) with CRS, but 0.67 (95% CI=0.46-0.94) with TC alone, illustrating the superior calibration of CRS. In a Cox model adjusted for age at testing, PRS had an HR per standard deviation (SD) of 1.48 (95% CI=1.33-1.64, p=2.55×10-13); the HR/SD was 1.43 (95% CI=1.29-1.59, p=1.61×10-11) after adjusting for family history. In a bivariate analysis using both CRS and TC to predict time to BC, CRS added significantly to the model after accounting for TC (HR/SD=2.89, 95% CI=2.12-3.94, p=1.20×10-11), whereas TC did not add significant information after accounting for CRS. 15,986 (12.3%) women were above the CRS high-risk threshold, including 123 with events. A total of 10,248 (7.9%) women were reclassified by the CRS model compared to the TC model. Among women who were classified as high-risk by TC, 32.6% were reclassified as low-risk by CRS; among those classified as low-risk by TC, 4.3% were reclassified as high-risk by CRS. The CRS high-risk group experienced events at over three times the rate of the low-risk group (HR=3.75, 95% CI=3.00-4.68, p=6.39×10-27). Conclusion: The CRS was well-calibrated in predicting BC and significantly improved upon a traditional risk factor model. Clinical use of the CRS may lead to improved BC prevention and screening strategies. Table: Absolute risk calibration by 5-year risk decile Incidence is reported per 1,000 women-years. 34 breast cancers were observed per decile. Citation Format: Brent Mabey, Elisha Hughes, Braden Probst, Holly J. Pederson, Timothy Simmons, Brian Morris, Brooke Hullinger, Susan Domchek, Charis Eng, Monique Gary, Jennifer Klemp, Semanti Mukherjee, Vijai Joseph, Kenneth Offit, Olufunmilayo I. Olopade, Sandhya Pruthi, Allison W. Kurian, Mark E. Robson, Pat Whitworth, Susanne Wagner, Jerry Lanchbury, Thomas Slavin, Alexander Gutin. PD14-05 Prospective longitudinal validation of a breast cancer risk prediction model in a cohort of 130,058 women [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr PD14-05.
Abstract OT2-11-01: A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: interim results
Okera, Meena , Tine, Brian Andrew Van, Mita, Monica , Valdes-Albini, Frances , Ahn, Daniel H. , Mamuye, Admasu, Pelham, Joshua, Yuet, Amy, Yurewicz, Diana, Liu, Yanning, Sandri, Andrés Machado, Edenfield, William J. , Morikawa, Aki , Gradishar, William J. , Kumar, Rajiv , Hubbard, Joleen M. , Barve, Minal , Hamilton, Erika , Wainberg, Zev A.

Mayo Clinic

Cancer Research | March 2, 2023 | Volume: 83 | Issue: 5_Supplement | Pages: OT2-11-01-OT2-11-01

10.1158/1538-7445.sabcs22-ot2-11-01 Get It

Abstract MT-5111 is a 55kD engineered toxin body targeting HER2 in solid tumors that binds to an epitope distinct from trastuzumab and pertuzumab, offering potential combination strategies with other HER2-targeting agents. MT-5111 works by internalizing, self-routing through intracellular compartments to the cytosol, and inducing potent cell-kill via the enzymatic and permanent inactivation of ribosomes. This is a phase 1 study in adults with advanced HER2+ solid tumors. MT-5111 is dosed weekly IV over 30 min in every 21-day cycle until disease progression, unacceptable toxicity, death, or withdrawn consent. The study has dose escalation (Part A) cohorts enrolling patients (pts) with any HER2+ cancer (CA) and expansion (Part B) cohorts for HER2+ breast cancer (BC), Gastric or Gastroesophageal junction adenocarcinoma (GEA), or other HER2+ solid CA. As of 30 June 2022, 42 total pts had enrolled (36 in Part A on 0.5-23 µg/kg/dose, 6 pts with BC in Part B1 on 10 µg/kg/dose). Median age 65 years, 28 (66.78%) pts were female, median of 4 prior systemic and 2 prior HER2-targeting treatment (tx). 17 pts with BC, 6 with biliary CA, 9 with GEA, and 10 with other solid CA have enrolled. Of the 17 BC pts, 15 received ≥ 10 µg/kg/dose. Tx emergent adverse events (TEAEs) have been reported in 40 (95%) pts, and tx-related AEs (TRAE) occurred in 23 (55%) pts. No pt experienced G4-G5 TRAE. G1 troponin elevations were noted in 5 pts without clinical signs of cardiotoxicity (1 pt 6.75 µg/kg, 2 pts 10 µg/kg, 1 pt 17 µg/kg, 1 pt 23 µg/kg). Reversible G1/G2 infusion-related reactions were reported in 2 pts. Tx-related G1-G3 rash was observed in 5 pts (4 pts ≥ 10 µg/kg/dose); maculopapular in 2 pts, acneiform in 1 pt and associated with pruritus in 3 pts. The G3 rash developed one wk after first dose of 23 µg/kg, was declared a DLT, improved with systemic steroid therapy and the pt continued tx at the same dose without recurrence. Best overall response per RECIST thus far is stable disease (SD) in 17 pts, non-CR/non-PD in 1 pt, and progressive disease (PD) in 14 pts. 1 pt had non-CR/non-PD for 30 wks (1 μg/kg, BC); 1 pt had SD for 24wks (10 μg/kg, pancreatic); 1 pt is on tx with SD through 8 cycles (10 μg/kg, BC). Of the 10 BC pts who received ≥ 10 μg/kg/dose, the best response was 5 SD. The mean serum concentration of MT-5111 has increased in a dose-proportional manner starting at 6.75µg/kg/dose (Table 1). The soluble HER2 (sHER2) levels at end of tx were higher compared to baseline in cohorts that received ≤ 4.5µg/kg/dose, but similar or lower in cohorts that received ≥ 6.75µg/kg/dose. Higher MT-5111 doses have been well tolerated and may saturate circulating sHER2, leading to more predictable serum concentrations and tumor penetration. The Cmax in humans at doses ≥6.75 µg/kg/dose is above the in vitro IC50 for high HER2+ cell lines (0.029nM) and at 17 µg/kg/dose, above the IC50 for moderate HER2+ cells (1.6nM). In conclusion, the dose proportionate increase in serum concentration with levels above the in vitro IC50 and the leveling off/reduction of sHER2 indicate exposure to MT-5111 is at clinically therapeutic levels. Skin toxicity at higher doses may indicate on-target effect as observed in other EGFR-targeted therapies where it is associated with clinical response and a better prognosis. sHER2 biomarker data is expected for all cohorts with PK correlation and 23µg/kg safety and efficacy data. PK profile of MT-5111, C1D1 values Citation Format: Meena Okera, Brian A. Van Tine, Joleen M. Hubbard, Minal Barve, Erika Hamilton, Monica M. Mita, Frances Valdes-Albini, Daniel Ahn, Admasu Mamuye, Joshua Pelham, Amy Yuet, Diana Yurewicz, Yanning Liu, Andres Machado Sandri, William J. Edenfield, Aki Morikawa, William Gradishar, Rajiv Kumar, Zev A. Wainberg. A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: interim results [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr OT2-11-01.
Effects of a Community-Based Intervention on BMI Trends in a Preschool Population: The Food and Fitness Initiative
Miccoli, Antonela , Hansen, Carina , Smith, Latasha M. , Lynch, Brian , Toussaint, Loren

Mayo Clinic

Pediatrics | March 1, 2023 | Volume: 147 | Issue: 3_MeetingAbstract | Pages: 764-766

10.1542/peds.147.3ma8.764 Get It

Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes
Waller, Rosalie G. , Hanson, Heidi A. , Avery, Brian J. , Madsen, Michael J. , Sborov, Douglas W. , Camp, Nicola J. , Griffin, R. L. , Waller, Rosalie G , Griffin, Rosalie

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 1, 2023 | Volume: 32 | Issue: 5 | Pages: 708-717

10.1158/1055-9965.epi-22-0798 | PMID 36857768 Get It

Abstract Background: Transcriptome studies are gaining momentum in genomic epidemiology, and the need to incorporate these data in multivariable models alongside other risk factors brings demands for new approaches. Methods: Here we describe SPECTRA, an approach to derive quantitative variables that capture the intrinsic variation in gene expression of a tissue type. We applied the SPECTRA approach to bulk RNA sequencing from malignant cells (CD138+) in patients from the Multiple Myeloma Research Foundation CoMMpass study. Results: A set of 39 spectra variables were derived to represent multiple myeloma cells. We used these variables in predictive modeling to determine spectra-based risk scores for overall survival, progression-free survival, and time to treatment failure. Risk scores added predictive value beyond known clinical and expression risk factors and replicated in an external dataset. Spectrum variable S5, a significant predictor for all three outcomes, showed pre-ranked gene set enrichment for the unfolded protein response, a mechanism targeted by proteasome inhibitors which are a common first line agent in multiple myeloma treatment. We further used the 39 spectra variables in descriptive modeling, with significant associations found with tumor cytogenetics, race, gender, and age at diagnosis; factors known to influence multiple myeloma incidence or progression. Conclusions: Quantitative variables from the SPECTRA approach can predict clinical outcomes in multiple myeloma and provide a new avenue for insight into tumor differences by demographic groups. Impact: The SPECTRA approach provides a set of quantitative phenotypes that deeply profile a tissue and allows for more comprehensive modeling of gene expression with other risk factors.
The certified child life specialist: A novel resource in the pediatric primary care clinic for managing children's pain during routine immunizations
Gregory, Seth W. , Aul, Andrea J., Lodermeier, Tara M., Rodemeyer, Jennifer L., Weaver, Amy L. , Lynch, Brian , Aul, Andrea J.

Mayo Clinic

Paediatric and Neonatal Pain | March 1, 2023 | Volume: 5 | Issue: 3 | Pages: 66-75

10.1002/pne2.12101 | PMID 37744282 Get It

Abstract This study evaluated the effect of the Certified Child Life Specialist (CCLS) on pediatric pain and pain management during routine immunization administration in the pediatric primary care clinic. Children 4–12 years of age ( n = 125) presenting for a well child physical examination at a rural primary care clinic were selected to receive standard nursing care or standard nursing care plus CCLS support during routine immunization administration. Patient reported pain was measured using the Faces Pain Scale‐Revised (FPS‐R), and patient behavioral responses were measured during immunization administration using the Children's Emotional Manifestation Scale (CEMS). The performance of psychosocial interventions and administration of topical pain‐relieving interventions were measured between both groups. CCLS support was associated with fewer negative emotional behaviors during immunization administration among 7‐ to 12‐year‐old children and a significantly higher provision of psychosocial interventions and topical pain‐relieving interventions among all ages. This study demonstrates that the presence of a CCLS can increase the provision of psychosocial and pain‐relieving interventions and reduce distress during immunization administration in a busy pediatric primary care clinic.